RUOResearch Use Only · Not FDA-cleared

Pharmacogenomics
Report

How your body processes medications. Key drug-metabolism genes with CPIC Level A clinical action guidance -- the report your physician needs before writing your next prescription.

⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.

📄
Download a sample report

See a fully rendered example -- real RSIDs, peer-reviewed citations, and clinical action guidance -- before you commit.

↓ Download sample
Key variants

RSIDs analyzed in this panel

Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.

rs4149056
SLCO1B1 *5 · Statin myopathy (CPIC Level A)
Highest-evidence-tier PGx interaction in the panel. Your report shows your genotype and CPIC-graded prescribing recommendation.
rs3892097
CYP2D6 *4 · SSRIs, opioids, tamoxifen
Determines metabolizer status for a wide range of common medications. Your report shows your genotype and personalized dosing guidance.
rs4244285
CYP2C19 *2 · clopidogrel, PPIs
Affects activation of clopidogrel and metabolism of several PPIs. Your report shows your genotype and clinical interpretation.
rs1799853
CYP2C9 *2 · warfarin, NSAIDs
Affects clearance of warfarin and several NSAIDs. Your report shows your genotype and personalized guidance.
Evidence base

Supporting literature

CPIC Statin/SLCO1B1 Guideline v3.0 (Oct 2025 update) · cpicpgx.org. SEARCH Collaborative Group NEJM 2008 (SLCO1B1 rs4149056 · myopathy OR=4.5 heterozygous, OR=17 homozygous). PharmGKB CYP2D6/CYP2C19 Level 1A annotations. DPYD CPIC Level A (5-FU toxicity).

Why pharmacogenomics matters

An estimated 1 in 5 people carry a pharmacogenomic variant that significantly alters how they process a commonly prescribed medication. CYP2D6 poor metabolizers accumulate toxic drug levels at standard doses. SLCO1B1 intermediate carriers face a 4.5x increased myopathy risk with simvastatin. These interactions are preventable -- with the right information shared with the right physician.

CPIC Level A -- the highest clinical evidence tier

AuraGen PGx reports follow Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines -- the international gold standard for translating genotype to prescribing recommendations. Level A means the evidence is sufficient to require clinical action. SLCO1B1 rs4149056 plus simvastatin is one of the most clinically proven pharmacogenomic interactions in medicine.

⚠ Research Use Only (RUO)

This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com

Standalone Clinical Report
Standalone
Physician sign-off required · available with WES or WGS kit
  • ✓28-gene panel · 51 drugs · 6 clinical specialties -- metabolism, drug transport, and receptor genes
  • ✓Highlights: CYP2D6 · CYP2C19 · CYP3A4/5 · CYP2C9 -- the four major metabolizing CYPs
  • ✓SLCO1B1 -- statin myopathy risk (CPIC Level A · highest evidence tier)
  • ✓VKORC1/CYP2C9 -- warfarin and anticoagulant sensitivity
  • ✓DPYD -- 5-fluorouracil chemotherapy toxicity safety
  • ✓TPMT/NUDT15 -- thiopurine myelosuppression risk
  • ✓Physician-formatted PGx summary letter included
Unlock this panel →↓ Download sample report

⚠ Research Use Only · Not FDA cleared

Other reports
Skin Genomics ReportIncludedGenetic Wellness ReportIncludedGLP-1 & Metabolic Response$89Cardiovascular Chain Report$129View all kits→